Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma

Trial Profile

Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Fludarabine; Interleukin-2; Mesna
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 20 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top